Search for Clinical Trial Results

Sponsored By

Factor XIII Deficiency - 9 Studies Found

Status Study
Completed Study Name: A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Condition: Factor XIII Deficiency
Date: 2009-04-21
Interventions: Biological: FXIII Concentrate (Human) Doses will be guided
Completed Study Name: An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Condition: Factor XIII Deficiency
Date: 2009-07-23
Interventions: Biological: FXIII Concentrate (Human) (FXIII) Doses will b
Completed Study Name: A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency
Condition: Factor XIII Deficiency
Date: 2009-04-16
Interventions: Biological: FXIII Concentrate (Human) Subjects will receive approximately 40 U/kg of FXIII every 28 days
Completed Study Name: Clinical Trial of Factor XIII (FXIII) Concentrate
Condition:
  • Hemophilia
  • Factor XIII Deficiency

Date: 2008-03-17
Interventions: Drug: Fibrogammin P Prophylaxis treatment
Completed Study Name: Wound Healing Abnormalities in Major Abdominal Surgery
Condition:
  • Impaired Wound Healing
  • Factor XIII Deficiency

Date: 2008-08-14
Completed Study Name: Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
Condition:
  • Congenital Bleeding Disorder
  • Congenital FXIII Deficiency

Date: 2009-09-15
Interventions: Drug: catridecacog Monthly administration of recombinant factor XIII as preventative treatment of bleedi
Completed Study Name: Factor XIII and Pulmonary Embolism in Neurosurgical Patients
Condition:
  • Brain Tumor
  • Vascular Lesion
  • Factor X
    Date: 2010-04-16
Completed Study Name: Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
Condition:
  • Congenital Bleeding Disorder
  • Congenital FXIII Deficiency

Date: 2003-03-18
Interventions: Drug: catridecacog Single doses of rFXIII administered intravenously (IV) to two subjects in each of the
Completed Study Name: Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
Condition:
  • Congenital Bleeding Disorder
  • Congenital FXIII Deficiency

Date: 2008-07-07
Interventions: Drug: catridecacog 35 IU/kg body weight, i.v. administration, once every 4 weeks